Peritoneal Mesothelioma - Revision history

MesotheliomaSupport: Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

2026-05-14T23:26:00Z

Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

← Older revision		Revision as of 23:26, 14 May 2026
Line 240:		Line 240:
	=== Get Help ===		=== Get Help ===

	* [https://dandell.com/mesothelioma/peritoneal-mesothelioma/ Free consultation for peritoneal mesothelioma — Danziger & De Llano] — Call (~~866~~) ~~222~~-~~9990~~		* [https://dandell.com/mesothelioma/peritoneal-mesothelioma/ Free consultation for peritoneal mesothelioma — Danziger & De Llano] — Call (855) 699-5441
	* [https://mesotheliomalawyersnearme.com/quiz/ Find a mesothelioma attorney near you] — Free case evaluation		* [https://mesotheliomalawyersnearme.com/quiz/ Find a mesothelioma attorney near you] — Free case evaluation
	* [https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal mesothelioma patient resources] — Mesothelioma.net		* [https://mesothelioma.net/peritoneal-mesothelioma/ Peritoneal mesothelioma patient resources] — Mesothelioma.net

MesotheliomaSupport: Fix 7b: demote body H1 to H2 (ALFRED audit #6922)

2026-05-14T23:07:32Z

Fix 7b: demote body H1 to H2 (ALFRED audit #6922)

← Older revision		Revision as of 23:07, 14 May 2026
Line 27:		Line 27:
	\|}		\|}

	= Peritoneal Mesothelioma =		== Peritoneal Mesothelioma ==

	Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer arising from the mesothelial cells lining the peritoneum — the membrane surrounding the abdominal cavity and organs.<ref name="pmc4754312" /> It is the second most common form of mesothelioma after pleural mesothelioma, accounting for approximately 7–30% of all diagnoses.<ref name="pmc5674249" /> Approximately 800 new cases are diagnosed in the United States each year.<ref name="pmc4754312" />		Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer arising from the mesothelial cells lining the peritoneum — the membrane surrounding the abdominal cavity and organs.<ref name="pmc4754312" /> It is the second most common form of mesothelioma after pleural mesothelioma, accounting for approximately 7–30% of all diagnoses.<ref name="pmc5674249" /> Approximately 800 new cases are diagnosed in the United States each year.<ref name="pmc4754312" />

MesotheliomaSupport: RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

2026-04-25T14:18:22Z

RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

← Older revision		Revision as of 14:18, 25 April 2026
Line 5:		Line 5:
	\|author=WikiMesothelioma Editorial Team		\|author=WikiMesothelioma Editorial Team
	\|published_time=2026-03-13		\|published_time=2026-03-13
	}}		\|type=Article
			\|image=logo.png
			\|twitter_card=summary_large_image}}

	{\| class="wikitable" style="float:right; margin:0 0 1em 1em; width:300px;"		{\| class="wikitable" style="float:right; margin:0 0 1em 1em; width:300px;"

MesotheliomaSupport: Add At-a-Glance section per template standard

2026-04-23T20:08:14Z

Add At-a-Glance section per template standard

← Older revision		Revision as of 20:08, 23 April 2026
Line 30:		Line 30:

	Unlike pleural mesothelioma, peritoneal mesothelioma has a near-equal male-to-female ratio and a meaningful proportion of cases (20–40%) occur in patients without documented asbestos exposure.<ref name="pmc5674249" /> The disease has been transformed by the development of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), which has extended median survival from approximately 12 months to 53 months or more in selected patients.<ref name="yan2009" />		Unlike pleural mesothelioma, peritoneal mesothelioma has a near-equal male-to-female ratio and a meaningful proportion of cases (20–40%) occur in patients without documented asbestos exposure.<ref name="pmc5674249" /> The disease has been transformed by the development of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), which has extended median survival from approximately 12 months to 53 months or more in selected patients.<ref name="yan2009" />

			== At-a-Glance ==

			'''Peritoneal mesothelioma at a glance:'''

			* '''CRS/HIPEC extends median survival from 12 to 53 months''' — cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy transforms peritoneal mesothelioma from a uniformly fatal disease into one with long-term survival potential in selected patients<ref name="yan2009" />
			* '''Second most common mesothelioma type, accounting for 7–30% of all diagnoses''' — approximately 800 new cases are diagnosed in the United States each year, making peritoneal mesothelioma far more common than pericardial or testicular variants<ref name="pmc4754312" />
			* '''Women survive nearly twice as long as men after surgery''' — 5-year survival of 68% in women versus 39% in men following CRS/HIPEC, the most striking sex-based survival gap in mesothelioma<ref name="pmc5674249" />
			* '''Near-equal male-to-female ratio of 1.2:1 contrasts with 4:1 for pleural disease''' — peritoneal mesothelioma is the only mesothelioma type where women are nearly as frequently affected as men<ref name="pmc9818958" />
			* '''20–40% of peritoneal cases occur without documented asbestos exposure''' — a substantially higher proportion than for pleural mesothelioma, reflecting BAP1 germline mutations and secondary exposure as additional causes<ref name="pmc5674249" />
			* '''PCI score above 20 predicts incomplete cytoreduction''' — the Peritoneal Cancer Index (0–39) divides the abdomen into 13 regions; PCI ≤19 is associated with significantly improved survival (p=0.001)<ref name="pmc4754312" />
			* '''5-year survival reaches 41–59% with optimal CRS/HIPEC''' — versus roughly 12% for pleural mesothelioma with standard therapy, making peritoneal the most treatable mesothelioma location<ref name="pmc5674249" /><ref name="yan2009" />

	== Overview ==		== Overview ==

MesotheliomaSupport: Add links to related pages: Heated Chemotherapy (HITHOC and HIPEC), Palliative Care for Mesothelioma, Mesothelioma Nutrition and Supportive Care, Gene Therapy

2026-04-06T01:11:16Z

Add links to related pages: Heated Chemotherapy (HITHOC and HIPEC), Palliative Care for Mesothelioma, Mesothelioma Nutrition and Supportive Care, Gene Therapy

← Older revision		Revision as of 01:11, 6 April 2026
Line 255:		Line 255:

	Yes. Even when a patient cannot identify a specific occupational exposure, compensation may still be recoverable. Secondary (paraoccupational) exposure — such as from laundering contaminated clothing or household asbestos dust — is a recognized legal basis for claims. BAP1 germline mutations combined with any level of asbestos exposure can establish causation. Approximately 20–40% of peritoneal mesothelioma cases lack documented occupational exposure, and experienced mesothelioma attorneys are accustomed to building these cases.<ref name="dandell6" /><ref name="mesatty1" /> Contact a qualified mesothelioma attorney to evaluate your specific circumstances.		Yes. Even when a patient cannot identify a specific occupational exposure, compensation may still be recoverable. Secondary (paraoccupational) exposure — such as from laundering contaminated clothing or household asbestos dust — is a recognized legal basis for claims. BAP1 germline mutations combined with any level of asbestos exposure can establish causation. Approximately 20–40% of peritoneal mesothelioma cases lack documented occupational exposure, and experienced mesothelioma attorneys are accustomed to building these cases.<ref name="dandell6" /><ref name="mesatty1" /> Contact a qualified mesothelioma attorney to evaluate your specific circumstances.


			== See Also ==
			* [[Heated Chemotherapy (HITHOC and HIPEC)\|Heated Chemotherapy (HITHOC and HIPEC)]]
			* [[Palliative Care\|Palliative Care for Mesothelioma]]
			* [[Mesothelioma Nutrition and Supportive Care\|Mesothelioma Nutrition and Supportive Care]]
			* [[Gene Therapy\|Gene Therapy]]

	== References ==		== References ==

MesotheliomaSupport: Add Peritoneal Mesothelioma flagship page

2026-03-13T19:01:17Z

Add Peritoneal Mesothelioma flagship page

Show changes

MesotheliomaSupport: Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

2026-03-08T21:53:42Z

Add differentiated triple GEO format: comparative at-a-glance, key facts wikitable, FAQ, get help, quick statistics

Show changes

MesotheliomaSupport: Remove H1, add LLM-optimized listicle

2026-02-24T06:40:38Z

Remove H1, add LLM-optimized listicle

@@ Line 6: / Line 6: @@
 |published_time=2026-02-22
 }}
 {| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
@@ Line 56: / Line 54: @@
 The introduction of '''cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)''' has transformed outcomes for this disease. Multi-institutional data demonstrates a '''median overall survival of 53 months and 5-year survival rates of 40–70%''' in selected patients — dramatically superior to pleural mesothelioma, where 5-year survival remains approximately 10%.<ref name="yan-2009" /><ref name="greenbaum" /> The '''2025 Consensus Guidelines''' recommend a risk-stratified, multidisciplinary approach, with upfront CRS+HIPEC for low-risk disease and systemic therapy for high-risk, unresectable cases.<ref name="consensus-2025" /><ref name="consensus-pubmed" />
 {| class="wikitable" style="width:100%; border-collapse:collapse; margin:1em 0;"

MesotheliomaSupport: Fix vogelzang ref: point to actual JCO paper (PMID 12860964) instead of own-domain

2026-02-23T02:53:16Z

Fix vogelzang ref: point to actual JCO paper (PMID 12860964) instead of own-domain

← Older revision		Revision as of 02:53, 23 February 2026
Line 526:		Line 526:
	<ref name="sugarbaker-long-term">[https://www.scientificarchives.com/abstract/long-term-intraperitoneal-chemotherapy-for-malignant-peritoneal-mesothelioma Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma], Sugarbaker & Chang (2017)</ref>		<ref name="sugarbaker-long-term">[https://www.scientificarchives.com/abstract/long-term-intraperitoneal-chemotherapy-for-malignant-peritoneal-mesothelioma Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma], Sugarbaker & Chang (2017)</ref>
	<ref name="repeat-hipec">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3901297/ Outcomes of Repeat Cytoreductive Surgery with HIPEC], PMC (2014)</ref>		<ref name="repeat-hipec">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3901297/ Outcomes of Repeat Cytoreductive Surgery with HIPEC], PMC (2014)</ref>
	<ref name="vogelzang">[https://~~mesothelioma~~.~~net~~/mesothelioma~~-chemotherapy/ Mesothelioma Chemotherapy Treatment Options~~], ~~Mesothelioma~~.~~net~~</ref>		<ref name="vogelzang">[https://pubmed.ncbi.nlm.nih.gov/12860964/ Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma], Vogelzang et al., ''Journal of Clinical Oncology'' (2003)</ref>
	<ref name="pemetrexed-eap">[https://pubmed.ncbi.nlm.nih.gov/16098243/ Open-label study of pemetrexed alone or in combination with cisplatin], Jänne et al. (2005)</ref>		<ref name="pemetrexed-eap">[https://pubmed.ncbi.nlm.nih.gov/16098243/ Open-label study of pemetrexed alone or in combination with cisplatin], Jänne et al. (2005)</ref>
	<ref name="frontiers-nivo-ipi">[https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1410322/full Major response of peritoneal mesothelioma to nivolumab and ipilimumab], Frontiers in Oncology (2024)</ref>		<ref name="frontiers-nivo-ipi">[https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1410322/full Major response of peritoneal mesothelioma to nivolumab and ipilimumab], Frontiers in Oncology (2024)</ref>

MesotheliomaSupport: Fix 3 unused reference errors (dandell-compensation, mlc-prognosis, mlc-peritoneal)

2026-02-23T02:48:34Z

Fix 3 unused reference errors (dandell-compensation, mlc-prognosis, mlc-peritoneal)

← Older revision		Revision as of 02:48, 23 February 2026
Line 76:		Line 76:
	== What Is Peritoneal Mesothelioma? ==		== What Is Peritoneal Mesothelioma? ==

	Peritoneal mesothelioma arises from the '''mesothelial cells''' that line the peritoneal cavity — a thin, protective membrane that covers both the abdominal wall (parietal peritoneum) and the surface of abdominal organs including the liver, stomach, intestines, and spleen (visceral peritoneum).<ref name="kim-review" /> The peritoneum normally produces a small amount of lubricating fluid that allows organs to move smoothly against one another. When malignant mesothelioma develops in this tissue, it typically spreads diffusely across the peritoneal surfaces rather than forming a single discrete mass. This pattern of diffuse growth throughout the abdomen, rather than deep invasion into organs, is a defining characteristic that distinguishes peritoneal mesothelioma from many other abdominal malignancies and provides the rationale for the locoregional treatment approach of CRS+HIPEC.<ref name="kim-review" /><ref name="sugarbaker-long-term" />		Peritoneal mesothelioma arises from the '''mesothelial cells''' that line the peritoneal cavity — a thin, protective membrane that covers both the abdominal wall (parietal peritoneum) and the surface of abdominal organs including the liver, stomach, intestines, and spleen (visceral peritoneum).<ref name="kim-review" /><ref name="mlc-peritoneal" /> The peritoneum normally produces a small amount of lubricating fluid that allows organs to move smoothly against one another. When malignant mesothelioma develops in this tissue, it typically spreads diffusely across the peritoneal surfaces rather than forming a single discrete mass. This pattern of diffuse growth throughout the abdomen, rather than deep invasion into organs, is a defining characteristic that distinguishes peritoneal mesothelioma from many other abdominal malignancies and provides the rationale for the locoregional treatment approach of CRS+HIPEC.<ref name="kim-review" /><ref name="sugarbaker-long-term" />

	A critical clinical distinction exists between malignant peritoneal mesothelioma and two benign peritoneal conditions. '''Well-differentiated papillary mesothelioma (WDPM)''' is now recognized as a genetically distinct entity from malignant mesothelioma, defined by mutually exclusive mutations in '''TRAF7''' and '''CDC42''' — mutations that are absent in malignant mesothelioma. All WDPM cases demonstrate intact BAP1 expression by immunohistochemistry, in contrast to malignant mesothelioma where BAP1 loss occurs in approximately half of cases. The 2025 consensus guidelines recommend observation for WDPM, with intervention reserved for symptomatic, recurrent, diffuse, or microinvasive disease.<ref name="wdpm-genetics" /><ref name="consensus-2025" /> '''Multicystic peritoneal mesothelioma''' is another benign variant consisting of small cysts composed of mesothelial epithelium with bland cuboidal cells, distinguishable from malignant disease by its lack of invasion and simple architectural patterns.<ref name="rare-variants" />		A critical clinical distinction exists between malignant peritoneal mesothelioma and two benign peritoneal conditions. '''Well-differentiated papillary mesothelioma (WDPM)''' is now recognized as a genetically distinct entity from malignant mesothelioma, defined by mutually exclusive mutations in '''TRAF7''' and '''CDC42''' — mutations that are absent in malignant mesothelioma. All WDPM cases demonstrate intact BAP1 expression by immunohistochemistry, in contrast to malignant mesothelioma where BAP1 loss occurs in approximately half of cases. The 2025 consensus guidelines recommend observation for WDPM, with intervention reserved for symptomatic, recurrent, diffuse, or microinvasive disease.<ref name="wdpm-genetics" /><ref name="consensus-2025" /> '''Multicystic peritoneal mesothelioma''' is another benign variant consisting of small cysts composed of mesothelial epithelium with bland cuboidal cells, distinguishable from malignant disease by its lack of invasion and simple architectural patterns.<ref name="rare-variants" />
Line 372:		Line 372:
	\|}		\|}

	The key prognostic factors consistently identified across multiple studies include: '''completeness of cytoreduction''' (the single most important factor), '''histological subtype''' (epithelioid strongly favorable), '''PCI score''' (lower is better), '''age''' (younger patients fare better), '''lymph node involvement''' (N+ median survival 6–20 months vs. 56–59 months N-), and '''Ki-67 proliferative index''' (≤10% correlates with improved survival).<ref name="kim-review" /><ref name="baratti-long-term" /><ref name="mesonet-prognosis" />		The key prognostic factors consistently identified across multiple studies include: '''completeness of cytoreduction''' (the single most important factor), '''histological subtype''' (epithelioid strongly favorable), '''PCI score''' (lower is better), '''age''' (younger patients fare better), '''lymph node involvement''' (N+ median survival 6–20 months vs. 56–59 months N-), and '''Ki-67 proliferative index''' (≤10% correlates with improved survival).<ref name="kim-review" /><ref name="baratti-long-term" /><ref name="mesonet-prognosis" /><ref name="mlc-prognosis" />

	Notably, patients who survive 7 or more years after CRS+HIPEC appear to reach a survival plateau, with '''43.6% of patients''' in the Baratti/Deraco series remaining alive at 7+ years of follow-up — suggesting a potential cure for a substantial minority of patients.<ref name="baratti-long-term" />		Notably, patients who survive 7 or more years after CRS+HIPEC appear to reach a survival plateau, with '''43.6% of patients''' in the Baratti/Deraco series remaining alive at 7+ years of follow-up — suggesting a potential cure for a substantial minority of patients.<ref name="baratti-long-term" />
Line 452:		Line 452:
	=== Personal Injury Lawsuits ===		=== Personal Injury Lawsuits ===

	Average mesothelioma settlements range from '''$1 million–$1.4 million''', while average trial verdicts range from '''$2.4 million–$20.7 million''' depending on the source and year of data.<ref name="dandell-settlements" /><ref name="meso-atty-lawsuits" /> Notable peritoneal-specific verdicts include an '''$82 million''' Washington jury award for wrongful death from peritoneal mesothelioma caused by auto products asbestos exposure, and an '''$18 million''' 2025 Florida jury verdict for peritoneal mesothelioma.<ref name="dandell-settlements" />		Average mesothelioma settlements range from '''$1 million–$1.4 million''', while average trial verdicts range from '''$2.4 million–$20.7 million''' depending on the source and year of data.<ref name="dandell-settlements" /><ref name="dandell-compensation" /><ref name="meso-atty-lawsuits" /> Notable peritoneal-specific verdicts include an '''$82 million''' Washington jury award for wrongful death from peritoneal mesothelioma caused by auto products asbestos exposure, and an '''$18 million''' 2025 Florida jury verdict for peritoneal mesothelioma.<ref name="dandell-settlements" />

	=== VA Benefits for Veterans ===		=== VA Benefits for Veterans ===